Latest News about NanoViricides
Recent news which mentions NanoViricides
   A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
   
  
  
  January 31, 2024
  From Benzinga
 
   NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
   
  January 08, 2024
  Tickers 
   NNVC
  
  
  From Benzinga
 
   As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
   
  
  
  December 18, 2023
  From Benzinga
 
   Is This Ticker That InvestorObservers Expects To Soar By More Than 350% Next Year On Your Watchlist?
   
  
  November 30, 2023
  From Benzinga
 From Benzinga
 
   Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
   
  
  
  September 26, 2023
  From Benzinga
 
   NanoViricides progressing well with new Covid study
   
  
  
 August 31, 2023
  
   SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
   
  
  
  July 18, 2023
  From Benzinga
 From Benzinga
 From Benzinga
 From Benzinga
 
   A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
   
  
  
  March 20, 2023
  From Benzinga
 
   European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy
   
  August 26, 2022
  Tickers 
   LGVN
  
  
  From Benzinga
 
   European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy
   
  August 26, 2022
  Tickers 
   LGVN
  
  
  From Benzinga
 
   Omicron BA.4/5 Subvariants Are More Contagious And More Treatment-Resistant, But This Biopharma Reports Working On A Potential Breakthrough
   
  
  
  August 03, 2022
  From Benzinga
 From Benzinga
 From Benzinga
 
   NanoViricides Reports That It Has Begun Drug Development To Combat Recent Cases Of Severe Pediatric Hepatitis
   
  
  May 16, 2022
  From Benzinga
 From Benzinga
 
   Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts
   
  
  
  January 19, 2022
  From Benzinga
 From Benzinga
 
   NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market
   
  
  
  December 20, 2021
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 

